Giant cell arteritis during COVID-19 pandemic

Simão, Luciano Mesquita; Messias, André

doi:10.5935/0004-2749.202100114

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion2

Sirs1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(2022) 18 Case 22 Case series 1 Following disease -Jonathan et al (2021) 23 Case report 1 Following disease -Oda et al (2020) 5 Case report 1 Following disease -…”

Section: Sirsmentioning

confidence: 99%

Giant cell arteritis after COVID-19 vaccination/disease: suggestions for further shots?

et al. 2022

View full text Add to dashboard Cite

“…(2022) 18 Case 22 Case series 1 Following disease -Jonathan et al (2021) 23 Case report 1 Following disease -Oda et al (2020) 5 Case report 1 Following disease -…”

Section: Sirsmentioning

confidence: 99%

Giant cell arteritis after COVID-19 vaccination/disease: suggestions for further shots?

et al. 2022

View full text Add to dashboard Cite

“… 15 Literature from several parts of the world observed the association of COVID-19 and giant-cell arteritis. 16 - 18 …”

Section: Discussionmentioning

confidence: 99%

“…15 Literature from several parts of the world observed the association of COVID-19 and giant-cell arteritis. [16][17][18] Therefore, it is wise to suspect GCA in those over 50 years of age presenting with symptoms in one or both eyes, or persistent frontal or parietal headache (Table 1). A high rate of suspicion, prompt investigation, and treatment promptly are vital to avoid permanent vision loss.…”

Section: Discussionmentioning

confidence: 99%

A Case Report of Post COVID19 Giant Cell Arteritis and Polymyalgia Rheumatica With Visual Loss

Mursi

Mirghani

Elbeialy

2022

Clin Med Insights Case Rep

View full text Add to dashboard Cite

COVID-19 shares some features of giant-cell arteritis, in which the diagnosis needs a high suspicion for prompt investigation and therapy. When the diseases coexist this might lead to diagnosis delay with grave consequences. We reported a case of a post-COVID-19 giant cell arteritis and polymyalgia rheumatica with visual loss. We treated the patient with pulse methylprednisolone 1 gm daily for 3 consecutive days followed by 60 mg prednisolone for 4 weeks until normalization of ESR, and then, gradual withdrawal. Oral Paracetamol, vitamin-D3, and calcium carbonate were added to the treatment regimen. The headache continued, so, we started perineural injection therapy (PIT) once daily, for 6 sessions, at which the headache was completely resolved after the third injection. The vision was regained completely after the sixth injection.

show abstract

Giant cell arteritis during COVID-19 pandemic

Cited by 2 publications

References 0 publications

Giant cell arteritis after COVID-19 vaccination/disease: suggestions for further shots?

Giant cell arteritis after COVID-19 vaccination/disease: suggestions for further shots?

A Case Report of Post COVID19 Giant Cell Arteritis and Polymyalgia Rheumatica With Visual Loss

Contact Info

Product

Resources

About